Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
$8.25
+0.6%
$8.41
$3.51
$14.44
$704.32M0.681.20 million shs152,536 shs
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
$3.95
-2.0%
$3.94
$2.14
$6.82
$169.39M1.2384,869 shs42,630 shs
Immunome, Inc. stock logo
IMNM
Immunome
$9.78
+3.1%
$8.06
$5.15
$16.81
$850.98M1.94915,888 shs340,828 shs
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$12.07
-4.4%
$10.52
$8.18
$29.56
$920.17M2.15884,692 shs479,768 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
+0.99%+6.22%-4.09%-8.89%+121.62%
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
-2.18%-4.05%+5.22%-28.92%+54.41%
Immunome, Inc. stock logo
IMNM
Immunome
-0.84%+5.21%+19.52%+6.27%-39.55%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-1.25%+3.87%+24.07%-4.25%-21.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.9276 of 5 stars
3.70.00.04.73.60.80.6
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
1.35 of 5 stars
3.51.00.00.02.50.00.0
Immunome, Inc. stock logo
IMNM
Immunome
1.7865 of 5 stars
3.50.00.00.02.82.50.0
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.1429 of 5 stars
4.41.00.00.02.00.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
3.33
Buy$44.00433.33% Upside
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
3.00
Buy$8.00102.53% Upside
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$23.33138.58% Upside
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
2.83
Moderate Buy$30.18150.01% Upside

Current Analyst Ratings Breakdown

Latest DMAC, NRIX, AVXL, and IMNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/13/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00 ➝ $21.00
4/29/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
4/9/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$32.00 ➝ $25.00
4/9/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$36.00 ➝ $35.00
4/9/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $27.00
4/7/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
4/7/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
4/2/2025
Immunome, Inc. stock logo
IMNM
Immunome
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$23.00
4/2/2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
3/31/2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00 ➝ $42.00
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/A$1.42 per shareN/A
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/A$1.35 per shareN/A
Immunome, Inc. stock logo
IMNM
Immunome
$10.94M77.80N/AN/A$2.77 per share3.53
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
$56.42M16.31N/AN/A$7.44 per share1.62
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
-$19.38M-$0.64N/AN/AN/AN/A-43.67%-40.81%8/6/2025 (Estimated)
Immunome, Inc. stock logo
IMNM
Immunome
-$106.81M-$3.18N/AN/AN/A-3,014.59%-48.63%-41.62%8/11/2025 (Estimated)
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$193.57M-$2.80N/AN/AN/A-354.85%-53.65%-38.59%7/10/2025 (Estimated)

Latest DMAC, NRIX, AVXL, and IMNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/10/2025Q2 2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.73N/AN/AN/A$16.26 millionN/A
5/13/2025Q2 2025
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
-$0.16-$0.13+$0.03-$0.13N/AN/A
5/13/2025Q1 2025
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
-$0.18-$0.18N/A-$0.18N/AN/A
5/12/2025Q1 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million
4/8/2025Q1 2025
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 million
3/19/2025Q4 2024
Immunome, Inc. stock logo
IMNM
Immunome
-$0.68-$0.84-$0.16-$1.28$3.07 million$2.74 million
3/17/2025Q4 2024
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
-$0.17-$0.18-$0.01-$0.18N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/AN/AN/AN/AN/A
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
N/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
N/A
9.45
9.45
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
N/A
11.81
11.81
Immunome, Inc. stock logo
IMNM
Immunome
N/A
6.17
6.17
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A
6.46
6.46

Institutional Ownership

CompanyInstitutional Ownership
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
31.55%
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
10.12%
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
11.40%
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
7.30%
Immunome, Inc. stock logo
IMNM
Immunome
8.60%
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
7.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anavex Life Sciences Corp. stock logo
AVXL
Anavex Life Sciences
4085.37 million75.71 millionOptionable
DiaMedica Therapeutics Inc. stock logo
DMAC
DiaMedica Therapeutics
2042.88 million39.68 millionOptionable
Immunome, Inc. stock logo
IMNM
Immunome
4087.01 million72.92 millionOptionable
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
30076.24 million70.42 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anavex Life Sciences stock logo

Anavex Life Sciences NASDAQ:AVXL

$8.25 +0.05 (+0.61%)
As of 01:52 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

DiaMedica Therapeutics stock logo

DiaMedica Therapeutics NASDAQ:DMAC

$3.95 -0.08 (-1.99%)
As of 01:53 PM Eastern

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Immunome stock logo

Immunome NASDAQ:IMNM

$9.78 +0.29 (+3.06%)
As of 01:52 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Nurix Therapeutics stock logo

Nurix Therapeutics NASDAQ:NRIX

$12.07 -0.56 (-4.43%)
As of 01:57 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.